Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

BiondVax

- PMLiVE

Merck agrees deal with Cidara Therapeutics worth almost $9.2bn

Cidara’s long-acting viral flu drug showed significant protection in phase 2 results

- PMLiVE

Sanofi reports improved patient outcomes from high-dose influenza vaccine

Study data shows a reduced risk of hospitalisation in older adults compared with standard-dose vaccines

- PMLiVE

NHS to initiate flu vaccine roll-outs for children from September

The roll-outs are part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

NHS England to offer millions of children flu vaccines from September

The rollout is part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

Real-world data highlights flu vaccine efficacy

Flu vaccinations prevented 7.5 million illnesses and 6,300 deaths from influenza in 2019/20

- PMLiVE

Potential universal flu vaccine shows efficacy in clinical trial

Candidate will now move forward into late-stage testing

- PMLiVE

NHS leaders warn of no-deal Brexit flu vaccine delays

Follows prior delay in production of the vaccine

- PMLiVE

Biotech profile: Tom Evans, CEO, Vaccitech.

Can UK-based company be first to develop a universal flu vaccine?

- PMLiVE

UK biotech Vaccitech raises £20m for universal flu shot

Aims to develop a vaccine targeting proteins in the core of the virus

UK flag

Universal flu vaccine heads for UK trials

New vaccine targets core proteins of the virus

- PMLiVE

Sanofi to pay $750m for vaccines biotech Protein Sciences

Adds US firm's recombinant-based influenza vaccine to its portfolio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links